Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

The catering manager for a local secondary school explained that making the decision to receive cold cap treatment was one of ...

The seven-year MS-STAT study, which involved almost 1,000 patients over 31 sites across the UK, concluded that simvastatin is ...

Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

The study, which utilised data from the French MS Registry, Italian MS Register, and the global MSBase Registry, analysed the outcomes of 282 patients with paediatric-onset MS.

A new study exposes the hidden bias behind delayed or denied treatments. It's time to break down these barriers and ensure everyone with #MS gets the care they deserve. ’ Therapeutic inertia ...

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...